← Back to patent-cliff list
地塞米松植入剂(EyePoint Pharma)
Tier C — Watch / tradeDexamethasone Implants(EyePoint Pharma)
Eyepoint Pharmaceuticals Inc
Originator
2018
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：GR
Brand：视姝、DEXYCU、Dexycu Kit
Indications (approved)：术后炎症
Regional status
US
撤市
EU
-
China
批准上市
2026-06-30
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Dexamethasone Implants(EyePoint Pharma)?
Approved indications include: 术后炎症.
When does the Dexamethasone Implants(EyePoint Pharma) patent expire?
No public expiry year is available for Dexamethasone Implants(EyePoint Pharma) yet; this page updates once verified.
How do I get a quote for Dexamethasone Implants(EyePoint Pharma) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24